Yves Humblet
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology, Cancer Genomics and Diagnostics, Lung Cancer Research Studies
Most-Cited Works
- → Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer(2004)5,036 cited
- → Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial(2012)2,847 cited
- → Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer(2013)2,231 cited
- → Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer(2007)1,996 cited
- → Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study(2010)1,795 cited
- → KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab(2007)824 cited
- → Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1(1999)786 cited
- → Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer(2004)773 cited
- → Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer(2009)642 cited
- → Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer(2014)599 cited